Pharmaceutical industry

Pharmaceuticals

Pharmaceutical companies are increasingly resorting to knowledge about biology for the production of medicines. Although chemically synthesised active ingredients still make up the largest share of the German pharmaceutical market, so-called biopharmaceuticals are catching up. Biopharmaceuticals are biomolecules that are too large to be produced chemically, or at least their production would not be efficient.

Investment in innovative cell culture systems

The manufacture of pharmaceutical and biotech products is usually associated with high material consumption. For this reason, the Giessen-based start-up Green Elephant Biotech has developed recyclable cell culture vessels. These not only reduce the carbon footprint by up to 90% compared to conventional disposable items, but also improve the growth conditions of the cells. This solution is now being further developed in a strategic partnership with the family-owned company Bürkert Fluid Control Systems.

Antibodies from diatoms for diagnostics

So-called antigen tests have been common knowledge since the coronavirus pandemic at the latest. They have long been used in medical diagnostics to detect certain viruses in saliva, blood or urine. However, the antibodies required for this are largely derived from animal cells or living animals. Now the Hanover-based start-up Phaeosynt wants to produce antibodies from algae. The German Federal Environmental Foundation (DBU) is funding the project with 125,000 euros.

“With communication standards to a digital biotech lab”

Engineer Felix Lenk is the founder and Managing Director of SmartLab Solutions GmbH. The spin-off from Dresden University of Technology develops hardware and IT solutions for the digitalised and automated laboratory of the future. These include the ‘Sens-o-Spheres’, a mobile measuring system the size of a pea that records important process parameters such as temperature in the culture medium of a bioreactor and transmits them to a base station.

Red light sensor modified for bacteria

In biotechnology, microorganisms have long been used to manufacture products for medicine, agriculture or the chemical industry or to boost industrial processes. However, bacteria are also becoming increasingly important in the diagnosis and treatment of diseases. New possibilities could now open up in the biotechnological application of bacteria. Researchers at the University of Bayreuth have laid the foundation.

A more sustainable painkiller

Cannabinoid substances – in the context of the current partial legalisation of cannabis, this somehow sounds like a narcotic. However, many of the 120 or so known cannabinoids are potent painkillers, including delta-9-THC (dronabinol), which doctors prescribe very specifically for certain chronic pains. Because the chemical synthesis used to date is not without its problems, researchers in the BigPharm project are looking for sustainable biotechnological alternatives.

DATI innovation communities

Bringing more good ideas into application and thus to companies and people: As a new component of its transfer and innovation promotion programme, the Federal Government intends to promote social and technological innovations in the future by setting up the German Agency for Transfer and Innovation (DATI). As an innovation agency, DATI will be based in Erfurt.

Residual biomass as a resource

According to estimates, more than 900 million tons of residual biomass are produced throughout the European Union every year. Only a small proportion of this is recycled and fermented in biogas plants, for example. The majority, around 98%, ends up in, incineration plants or landfill sites. But this is now set to change.